83 related articles for article (PubMed ID: 1450228)
1. Radioiodinated azomycin pyranoside (IAZP): a novel non-invasive marker for the assessment of tumor hypoxia.
Mannan RH; Mercer JR; Wiebe LI; Kumar P; Somayaji VV; Chapman JD
J Nucl Biol Med (1991); 1992; 36(1):60-7. PubMed ID: 1450228
[TBL] [Abstract][Full Text] [Related]
2. Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: a novel probe for the noninvasive assessment of tumor hypoxia.
Mannan RH; Mercer JR; Wiebe LI; Somayaji VV; Chapman JD
Radiat Res; 1992 Dec; 132(3):368-74. PubMed ID: 1475360
[TBL] [Abstract][Full Text] [Related]
3. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia.
Mannan RH; Somayaji VV; Lee J; Mercer JR; Chapman JD; Wiebe LI
J Nucl Med; 1991 Sep; 32(9):1764-70. PubMed ID: 1880579
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside.
Lee HC; Kumar P; McEwan AJ; Wiebe LI; Mercer JR
Nucl Med Biol; 2000 Jan; 27(1):61-8. PubMed ID: 10755647
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Evaluation of Iodoglucoazomycin (I-GAZ), an Azomycin-Glucose Adduct with Putative Applications in Diagnostic Imaging and Radiotherapy of Hypoxic Tumors.
Kumar P; Elsaidi HR; Zorniak B; Laurens E; Yang J; Bacchu V; Wang M; Wiebe LI
ChemMedChem; 2016 Aug; 11(15):1638-45. PubMed ID: 27377671
[TBL] [Abstract][Full Text] [Related]
6. [131I]Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice.
Kumar P; McQuarrie SA; Zhou A; McEwan AJ; Wiebe LI
Nucl Med Biol; 2005 Aug; 32(6):647-53. PubMed ID: 16026712
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
Ballinger JR; Kee JW; Rauth AM
J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
[TBL] [Abstract][Full Text] [Related]
8. [99mTc]Technetium labelled PnAo-azomycin glucuronides: a novel class of imaging markers of tissue hypoxia.
Kumar P; Wiebe LI; Mannan RH; Zhang Z; Xia H; McEwan AJ
Appl Radiat Isot; 2002 Nov; 57(5):719-28. PubMed ID: 12433047
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and preliminary biological evaluation of 6-O-glucose-azomycin adducts for diagnosis and therapy of hypoxic tumors.
Kumar P; Shustov G; Liang H; Khlebnikov V; Zheng W; Yang XH; Cheeseman C; Wiebe LI
J Med Chem; 2012 Jul; 55(13):6033-46. PubMed ID: 22708968
[TBL] [Abstract][Full Text] [Related]
10. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of [(18)F]F-GAZ, a novel oxygen-mimetic azomycin-glucose conjugate, for imaging hypoxic tumor.
Wuest M; Kumar P; Wang M; Yang J; Jans HS; Wiebe LI
Cancer Biother Radiopharm; 2012 Oct; 27(8):473-80. PubMed ID: 22746267
[TBL] [Abstract][Full Text] [Related]
12. Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization.
Jette DC; Wiebe LI; Flanagan RJ; Lee J; Chapman JD
Radiat Res; 1986 Feb; 105(2):169-79. PubMed ID: 3952269
[TBL] [Abstract][Full Text] [Related]
13. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
14. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
Melo T; Duncan J; Ballinger JR; Rauth AM
J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
[TBL] [Abstract][Full Text] [Related]
15. Development of new markers for hypoxic cells: [131I]Iodomisonidazole and [131I]Iodoerythronitroimidazole.
Cherif A; Wallace S; Yang DJ; Newman RA; Harrod VL; Nornoo A; Inoue T; Kim CG; Kuang LR; Kim EE; Podoloff DA
J Drug Target; 1996; 4(1):31-9. PubMed ID: 8798876
[TBL] [Abstract][Full Text] [Related]
16. [Radiosensitizing effect of a 2-nitroimidazole hydroxamate (KIN-804) to murine tumors].
Tada T; Nakajima T; Onoyama Y; Nagasawa H; Hori H; Inayama S
Nihon Igaku Hoshasen Gakkai Zasshi; 1992 May; 52(5):688-90. PubMed ID: 1508643
[TBL] [Abstract][Full Text] [Related]
17. Autoradiographic distribution of [14C]-labelled pimonidazole in rhabdomyosarcoma-bearing rats and pigmented mice.
Laurent F; Benard P; Canal P; Soula G
Cancer Chemother Pharmacol; 1988; 22(4):308-15. PubMed ID: 3168144
[TBL] [Abstract][Full Text] [Related]
18. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Ji M; Bloomer WD
Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers.
Li Z; Chu T; Liu X; Wang X
Nucl Med Biol; 2005 Apr; 32(3):225-31. PubMed ID: 15820757
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, biodistribution, and gamma camera imaging of 111In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts.
Longley C; Furmanski P; Dienhart DG; Lear J; Bloedow D; Kasliwal R; Bunn PA
Cancer Res; 1990 Sep; 50(18):5954-61. PubMed ID: 2393864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
